Williams, Thomas;
Chataway, Jeremy;
(2022)
Beyond ocrelizumab in primary progressive multiple sclerosis.
Nature Reviews Neurology
, 18
pp. 641-642.
10.1038/s41582-022-00724-8.
Preview |
Text
Chataway_Williams_v3.0_clean_1660931559_24_TW_JC.pdf Download (203kB) | Preview |
Abstract
Currently, the anti-CD20 monoclonal antibody ocrelizumab is the only approved treatment for primary progressive multiple sclerosis (PPMS). However, a new study suggests that other immunomodulatory disease-modifying therapies that are often used to treat relapsing forms of multiple sclerosis could be effective in people with PPMS who have evidence of active inflammatory disease.
| Type: | Article |
|---|---|
| Title: | Beyond ocrelizumab in primary progressive multiple sclerosis |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/s41582-022-00724-8 |
| Publisher version: | https://doi.org/10.1038/s41582-022-00724-8 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Multiple sclerosis, Neuroimmunology |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10157376 |
Archive Staff Only
 |
View Item |
